JPRN-UMIN000007702已完成未知
Clinical trial of rituximab in interstitial lung disease secondary to systemic sclerosis - Clinical trial of rituximab in interstitial lung disease secondary to systemic sclerosis
Department of Dermatology, The University of Tokyo0 个研究点目标入组 20 人开始时间: 2012年4月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)during treatment with equal drug 2)previous history of anaphylactic reactions to this drug 3)significant infection 4)significant liver damage 5)significant renal damage 6)less than or equal to 60% of %VC or 40% of %DLco 7)previous history of significant infection 8)pregnancy 9)breast-feeding 10)participating in other clinical trial within three months before the beginning of this trial 11)judged inappropriate for this study by the physicians
研究者
相似试验
已完成
2 期
Clinical trial of rituximab in interstitial lung disease secondary to systemic sclerosisInterstitial lung disease secondary to systemic sclerosisJPRN-jRCTs031180373Yoshizaki Ayumi33
未知
2 期
Clinical study for effectiveness of rituximab for acquired coagulopathyacquired coagulopathyJPRN-UMIN000024612Gunma University10
已完成
2 期
Prospective Trial of Rituximab for Primary Pulmonary Alveolar ProteinosisPulmonary Alveolar ProteinosisPrimary DiseaseNCT00552461East Carolina University10
尚未招募
2 期
Study of efficacy of rituximab drug for topical application in oral mucosa in pemphigus vulgaris patients.CTRI/2018/05/014187Dr SUJAY KHANDPUR
进行中（未招募）
1 期
Ruxolitinib for treatment of Covid-19 Patienten with acute respiratorydistress syndromeSARS-CoV-2 induced ARDSEUCTR2020-001732-10-DEPhilipps-Universität Marburg15